Browsing Tag
Halozyme Therapeutics
6 posts
Halozyme Therapeutics (HALO) completes $900m Elektrofi deal—what’s next for its royalty roadmap?
Halozyme finalizes $900M Elektrofi deal to strengthen its subcutaneous biologics platform. Discover how this move impacts future royalties and delivery formats.
Why Halozyme Therapeutics is raising $1.3bn in convertible notes and what it means for HALO stock
Halozyme Therapeutics raises $1.3B via convertible notes to refinance debt and fund growth. Find out what this means for biotech investors and royalty markets.
Top U.S. gainers: Regencell, Disney, Rockwell, and Tempus AI spark broad market rally
Explore which U.S. stocks surged on May 7, 2025, and why investors rotated into biotech, AI, and healthcare amid Fed pauses and macro uncertainty.
FDA approves Halozyme’s VYVGART Hytrulo for CIDP treatment
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA)…
Halozyme Therapeutics announces licensing deal with Acumen Pharmaceuticals for Alzheimer’s therapy advancement
Halozyme Therapeutics, Inc. has entered a pivotal global collaboration and non-exclusive licensing agreement with Acumen Pharmaceuticals. This partnership…
Halozyme Therapeutics to acquire specialty pharma company Antares Pharma for $960m
Halozyme Therapeutics, a California-based publicly-listed biotech company, has agreed to acquire New Jersey-based specialty pharma company Antares Pharma…